Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

481. Treatments for fatigue in multiple sclerosis: a rapid and systematic review Full Text available with Trip Pro

Treatments for fatigue in multiple sclerosis: a rapid and systematic review Treatments for fatigue in multiple sclerosis: a rapid and systematic review Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need

2000 NIHR HTA programme

482. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review Full Text available with Trip Pro

Disease-modifying drugs for multiple sclerosis: a rapid and systematic review Disease-modifying drugs for multiple sclerosis: a rapid and systematic review Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need

2000 NIHR HTA programme

483. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. Full Text available with Trip Pro

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. Treatment with interferon beta has been shown to help patients with established multiple sclerosis, but it is not known whether initiating treatment at the time of a first clinical demyelinating event is of value.We conducted a randomized, double-blind trial of 383 patients who had a first acute clinical demyelinating event (optic neuritis, incomplete transverse (...) myelitis, or brain-stem or cerebellar syndrome) and evidence of prior subclinical demyelination on magnetic resonance imaging (MRI) of the brain. After initial treatment with corticosteroids, 193 patients were randomly assigned to receive weekly intramuscular injections of 30 microg of interferon beta-1a and 190 were assigned to receive weekly injections of placebo. The study end points were the development of clinically definite multiple sclerosis and changes in findings on MRI of the brain. The trial

2000 NEJM Controlled trial quality: predicted high

484. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials

Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials Brusaferri F, Candelise L Authors' objectives To assess the effect of steroids on short- and long-term functional improvement and on the prevention of relapses (...) . The treatment duration and dose, and the severity of side-effects, were also evaluated. Searching MEDLINE and EMBASE were searched from January 1966 to December 1998 using the following terms: 'multiple sclerosis', 'optic neuritis', 'corticosteroids', 'steroids', 'ACTH' and 'randomised controlled clinical trials' with all subheadings. The reference lists of all the included trials and some reviews were checked. Study selection Study designs of evaluations included in the review Randomised controlled trials

2000 DARE.

485. Complementary and alternative therapies for treating multiple sclerosis symptoms: a systematic review

Complementary and alternative therapies for treating multiple sclerosis symptoms: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2000 DARE.

486. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review

Disease-modifying drugs for multiple sclerosis: a rapid and systematic review Disease-modifying drugs for multiple sclerosis: a rapid and systematic review Disease-modifying drugs for multiple sclerosis: a rapid and systematic review Clegg A, Bryant J, Milne R Authors' objectives To provide a rapid review of the effectiveness and costs of disease-modifying drugs in multiple sclerosis (MS). Searching Cochrane Database of Systematic Reviews, Cochrane Controlled Trials Register, NHS CRD's Database (...) NHS R&D Health Technology Assessment (HTA) Programme, project number 99/05/01. Bibliographic details Clegg A, Bryant J, Milne R. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. Health Technology Assessment 2000; 4(9): 1-101 Original Paper URL Other publications of related interest 1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials

2000 DARE.

487. Treatments for fatigue in multiple sclerosis: a rapid and systematic review

Treatments for fatigue in multiple sclerosis: a rapid and systematic review Treatments for fatigue in multiple sclerosis: a rapid and systematic review Treatments for fatigue in multiple sclerosis: a rapid and systematic review Branas P, Jordan R, Fry-Smith A, Burls A, Hyde C Authors' objectives To review evidence of the effects and overall effectiveness of promising interventions in the treatment of fatigue in multiple sclerosis (MS). Searching The authors searched MEDLINE (1966 to December (...) 1999), EMBASE (1974 to 1979), EMBASE (1980 to December 1999), the Cochrane Library 1999, Issue 4, using the index terms: 'amantadine', 'multiple sclerosis', 'pemoline'; and the textwords 'amantadine', 'symmetrel', 'multiple sclerosis', 'pemoline', 'cylert' and 'volital'. The authors also checked the citation lists from retrieved articles and contacted experts in the field for additional data. Study selection Study designs of evaluations included in the review Controlled trials with either a placebo

2000 DARE.

488. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life

Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life Parkin D, Jacoby A, McNamee P, Miller P, Thomas S, Bates D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Treatment of multiple sclerosis with interferon beta. Type of intervention Treatment. Economic study type Cost-effectiveness analysis; cost-utility analysis. Study population Patients suffering from relapsing-remitting multiple sclerosis. Setting Hospital and community settings. The study

2000 NHS Economic Evaluation Database.

489. Long term treatment of multiple sclerosis with interferon-beta may be cost effective

Long term treatment of multiple sclerosis with interferon-beta may be cost effective Long term treatment of multiple sclerosis with interferon-beta may be cost effective Long term treatment of multiple sclerosis with interferon-beta may be cost effective Kendrick M, Johnson K I Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of interferon (IFN)-beta for the treatment of multiple sclerosis (MS). Due to the lack of a cure for MS, IFN-beta is intended to slow the disease process. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised patients with MS. Setting The setting was not stated. The economic study was carried out in the UK. Dates to which

2000 NHS Economic Evaluation Database.

490. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations

A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations Miller D M, Weinstock-Guttman B, Bethoux F, Lee J C, Beck G, Block V, Durelli L, LaMantia L, Barnes D, Sellebjerg F, Rudick R A Authors' objectives To assess methylprednisolone (MP) at different doses, and in comparison with other (...) steroid products, in the treatment of multiple sclerosis exacerbations. Searching MEDLINE was searched from 1981 to 1998, and EMBASE from 1980 to 1998, combining 'Multiple Sclerosis' (as an index term) with 'Methylprednisolone' (either as an index term or in 'authors, title or abstract'). The references of identified articles and recent review articles were also examined. No restrictions on publication language were specified. Study selection Study designs of evaluations included in the review

2000 DARE.

491. Meta-analysis of clinical trials with copolymer 1 in multiple sclerosis

Meta-analysis of clinical trials with copolymer 1 in multiple sclerosis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2000 DARE.

492. Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review)

Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review) Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review) Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence (...) -based review) Gronseth G S, Ashman E J Authors' objectives To determine the effectiveness of evoked potential (EP)-identified silent lesions in diagnosing multiple sclerosis (MS). Searching MEDLINE was searched for articles published between 1966 and January 1998, using the terms 'multiple sclerosis' and 'evoked potential'. The bibliographies of retrieved articles were also examined. Study selection Study designs of evaluations included in the review No a priori inclusion criteria regarding

2000 DARE.

493. Treatments for fatigue in multiple sclerosis: a rapid and systematic review

Treatments for fatigue in multiple sclerosis: a rapid and systematic review Treatments for fatigue in multiple sclerosis: a rapid and systematic review Treatments for fatigue in multiple sclerosis: a rapid and systematic review Branas P, Jordan R, Fry-Smith A, Burls A, Hyde C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Branas P (...) , Jordan R, Fry-Smith A, Burls A, Hyde C. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technology Assessment 2000; 4(27): 1-61 Authors' objectives - To identify current treatments for fatigue in MS and their evidence-base. - To systematically review the evidence for those treatments that have been investigated in more than one rigorous study, in order to determine their effectiveness and cost-effectiveness. Authors' conclusions There is insufficient evidence

2000 Health Technology Assessment (HTA) Database.

494. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review

Disease-modifying drugs for multiple sclerosis: a rapid and systematic review Disease-modifying drugs for multiple sclerosis: a rapid and systematic review Disease-modifying drugs for multiple sclerosis: a rapid and systematic review Clegg A, Bryant J, Milne R Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Clegg A, Bryant J, Milne R (...) . Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. Health Technology Assessment 2000; 4(9): 1-101 Authors' objectives The aim of the report is to provide a rapid review of the effectiveness and costs of disease-modifying drugs in multiple sclerosis (MS). Authors' conclusions Evidence for the effectiveness of immunomodulatory drugs in MS is problematic because: - there are few good quality trials for each drug - trials often have methodological limitations or poor reporting

2000 Health Technology Assessment (HTA) Database.

495. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. (Abstract)

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Multiple sclerosis results from T-cell-dependent inflammatory demyelination of the central nervous system. Our objective was long-term suppression of inflammation with short-term monoclonal antibody treatment.We depleted 95% of circulating lymphocytes in 27 patients with multiple sclerosis by means of a 5-day pulse of the humanised anti-CD52 monoclonal antibody, Campath-1H. Clinical and haematological (...) mitogen-induced proliferation and interferon gamma secretion in vitro.Campath-1H causes the immune response to change from the Th1 phenotype, suppressing multiple sclerosis disease activity, but permitting the generation of antibody-mediated thyroid autoimmunity.

1999 Lancet Controlled trial quality: uncertain

496. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis

Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis Forbes R B, Lees A, Waugh N, Swingler R J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Interferon beta for secondary progressive multiple sclerosis. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population consisted of patients with secondary progressive multiple sclerosis. Setting The study setting was a hospital (specialist outpatient clinic). The economic

1999 NHS Economic Evaluation Database.

497. [Beta-interferon treatment in RRMS and secondary progressive multiple sclerosis]

[Beta-interferon treatment in RRMS and secondary progressive multiple sclerosis] Beta-interferon-behandling ved attakvis og sekundær progressiv dissemineret sklerose [Beta-interferon treatment in RRMS and secondary progressive multiple sclerosis] Beta-interferon-behandling ved attakvis og sekundær progressiv dissemineret sklerose [Beta-interferon treatment in RRMS and secondary progressive multiple sclerosis] Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Danish Centre for Evaluation and Health Technology Assessment (DACEHTA). Beta-interferon-behandling ved attakvis og sekundær progressiv dissemineret sklerose. [Beta-interferon treatment in RRMS and secondary progressive multiple sclerosis] Copenhagen: Danish Centre for Evaluation and Health Technology Assessment (DACEHTA

1999 Health Technology Assessment (HTA) Database.

498. Development of the protocol for the proposed trial of beta interferon in multiple sclerosis

Development of the protocol for the proposed trial of beta interferon in multiple sclerosis Development of the protocol for the proposed trial of beta interferon in multiple sclerosis Development of the protocol for the proposed trial of beta interferon in multiple sclerosis Rothwell P Citation Rothwell P. Development of the protocol for the proposed trial of beta interferon in multiple sclerosis. Health Technology Assessment Authors' conclusions Completed - No publication required in the HTA (...) monograph series. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Interferon-beta; Multiple Sclerosis; Randomized Controlled Trials as Topic Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber 32010000420 Date

1999 Health Technology Assessment (HTA) Database.

499. Beta intererons (1a and 1b) in elapsing-remitting and secondary progressive multiple sclerosis

Beta intererons (1a and 1b) in elapsing-remitting and secondary progressive multiple sclerosis Beta intererons (1a and 1b) in elapsing-remitting and secondary progressive multiple sclerosis Beta intererons (1a and 1b) in elapsing-remitting and secondary progressive multiple sclerosis Nicholson T, Milne R Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Nicholson T, Milne R. Beta intererons (1a and 1b) in elapsing-remitting and secondary progressive multiple sclerosis. Southampton: Wessex Institute for Health Research and Development (WIHRD) 1999 Authors' objectives This report considers the cost-effectiveness of the beta interferons (IFNB -1a and -1b) in the treatment of relapsing-remitting (RR) and IFNB-1b in the treatment of secondary progressive (SP) multiple sclerosis (MS). Authors' conclusions There is good evidence from

1999 Health Technology Assessment (HTA) Database.

500. Interferon beta treatment for multiple sclerosis (funded by DIHTA)

Interferon beta treatment for multiple sclerosis (funded by DIHTA) Interferon beta treatment for multiple sclerosis (funded by DIHTA) Interferon beta treatment for multiple sclerosis (funded by DIHTA) Danish Centre for Evaluation and Health Technology Assessment Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Danish Centre for Evaluation (...) and Health Technology Assessment. Interferon beta treatment for multiple sclerosis (funded by DIHTA) Copenhagen: Danish Centre for Evaluation and Health Technology Assessment (DACEHTA). 1999 Authors' objectives This report aims to include: 1) an analysis of the experience of interferon beta treatment for relapsing multiple sclerosis (MS), and 2) an account of the consequences of a possible widening of the range of patients being offered this treatment to include patients with secondary progressive MS

1999 Health Technology Assessment (HTA) Database.